Juan M. Sancho
Badalona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.
Journal: Transplantation and cellular therapy
Published: March 16, 2024
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
Journal: Transplantation and cellular therapy
Published: June 02, 2023
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
Journal: British journal of haematology
Published: March 07, 2023
Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain.
Journal: British journal of haematology
Published: January 28, 2022
Participatory action research intervention for improving sleep in inpatients with cancer.
Journal: Journal of clinical nursing
Published: November 06, 2021
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
Journal: Leukemia & lymphoma
Published: August 30, 2021
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
Journal: Haematologica
Published: July 21, 2021
Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.
Journal: Blood advances
Published: May 19, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Journal: Future oncology (London, England)
Published: February 02, 2021
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Journal: The Lancet. Haematology
Published: February 12, 2020
Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution.
Journal: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
Published: November 23, 2019
Last Updated: 09/26/2026